Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection
dc.contributor.author | Bernstein, DE | en_US |
dc.contributor.author | Foster, G | en_US |
dc.contributor.author | Dylla, D | en_US |
dc.contributor.author | Mauss, S | en_US |
dc.contributor.author | Nelson, D | en_US |
dc.contributor.author | Asselah, T | en_US |
dc.contributor.author | Flamm, S | en_US |
dc.contributor.author | Cooper, C | en_US |
dc.contributor.author | Liu, R | en_US |
dc.contributor.author | Viani, R | en_US |
dc.contributor.author | Wang, S | en_US |
dc.contributor.author | Mensa, F | en_US |
dc.contributor.author | Sulkowski, M | en_US |
dc.date.accessioned | 2020-07-15T15:34:57Z | |
dc.date.issued | 2017-10 | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/65703 | |
dc.format.extent | S490 - S490 | en_US |
dc.title | Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection | en_US |
dc.type | Conference Proceeding | |
dc.identifier.doi | 10.14309/00000434-201710001-00869 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439259002098&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 112 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Centre for Immunobiology [1121]